BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide with a uniquely broad healing profile — gut repair, connective tissue recovery, HPA axis modulation, and collagen synthesis. For women, its multi-system mechanism addresses several interconnected health priorities simultaneously.
BPC-157 promotes healing of the intestinal epithelium via EGF receptor upregulation and tight junction protein restoration. Women with IBS, IBD, or leaky gut syndrome show particular benefit — oral administration delivers BPC-157 directly to the gut lining for targeted repair.
Reduces cortisol-driven HPA overactivation, which in women disrupts the HPO axis — suppressing estrogen, LH, and FSH. By normalizing HPA activity, BPC-157 may support more regular cycles, improved libido, and better thyroid function in chronically stressed women.
Upregulates TGF-β and VEGF, driving collagen synthesis and angiogenesis in connective tissue. Women have higher rates of ACL, rotator cuff, and patellar tendon injuries relative to men — BPC-157's collagen-promoting effects directly address the connective tissue vulnerability that underlies these injury patterns.
Women typically use slightly lower doses than men due to body weight differences. Protocol selection depends on the primary target: gut healing uses oral administration, musculoskeletal injuries use subcutaneous injection.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Gut Protocol (Weeks 1–8) | 250 mcg twice daily | Morning + evening oral | Take on empty stomach. For IBS, IBD, leaky gut. Can continue 12+ weeks. |
| Injury Protocol (Weeks 1–2) | 400 mcg/day | Once daily SubQ | Near injury site. Loading phase to establish tissue levels. |
| Injury Protocol (Weeks 3–8) | 200–400 mcg/day | Once or twice daily SubQ | Reduce to 200 mcg if tolerating well. Twice daily for severe injuries. |
| Maintenance (Weeks 9–12) | 200 mcg/day | Once daily or 5x/week | Continue until full functional recovery. No PCT required. |
| Skin/Collagen Protocol | 200 mcg/day | Once daily SubQ abdomen | Combine with GHK-Cu topical for synergistic collagen support. |
| Benefit | Evidence Level | Mechanism | Timeframe |
|---|---|---|---|
| Gut healing (IBS/IBD) | Strong (rodent + human anecdote) | EGF receptor, tight junction restoration | 2–6 weeks |
| Tendon/ligament repair | Strong (rodent models) | FAK-paxillin, VEGF, collagen synthesis | 4–8 weeks |
| HPA axis / cortisol | Moderate | HPA modulation, dopamine/serotonin balance | 2–4 weeks |
| Skin & collagen quality | Moderate (indirect) | TGF-β, VEGF, fibroblast activation | 6–12 weeks |
| Systemic inflammation | Moderate | COX-2 modulation, NO system | 1–3 weeks |
BPC-157 combines well with several other peptides and compounds. These combinations are commonly used in women's health and recovery protocols.
| Compound | Synergy | Best For | Notes |
|---|---|---|---|
| TB-500 | Systemic anti-inflammatory + stem cell mobilization | Injury recovery, overtraining | Classic recovery stack — BPC local, TB-500 systemic |
| GHK-Cu | Collagen synthesis + skin remodeling | Skin quality, hair health, wound healing | Topical GHK-Cu + injectable BPC-157 for connective tissue |
| Sermorelin | GH pulse restoration + tissue repair | Anti-aging, body composition | GH supports collagen and lean mass; BPC-157 accelerates repair |
| NAD+ | Cellular energy + mitochondrial function | Fatigue, longevity, metabolic health | Complementary mechanisms — no known interactions |
No human safety data exists for BPC-157 during pregnancy or breastfeeding. Avoid use in these contexts until safety data is available.
No known interactions between BPC-157 and oral contraceptives or hormonal IUDs. BPC-157 does not affect estrogen or progesterone directly.
BPC-157 has immunomodulatory properties. Women with autoimmune conditions (Hashimoto's, lupus, RA) should consult a healthcare provider before use.
BPC-157 promotes angiogenesis (new blood vessel formation). Women with a history of hormone-sensitive cancers should avoid use — consult an oncologist.
≥99% purity, third-party COA verified. Use code HEALTH for 15% off.
Shop BPC-157 at Purgo LabsBPC-157 is researched in women for gut healing (IBS, leaky gut, IBD), musculoskeletal injury recovery, hormonal balance support via HPA axis modulation, skin and collagen health, and reducing chronic inflammation. Women report particular benefit for gut-related conditions and connective tissue injuries, where BPC-157's multi-mechanism healing profile addresses multiple systems simultaneously.
Research protocols for women typically use 200–400 mcg per day, slightly lower than the 250–500 mcg range used in men due to body weight differences. Subcutaneous injection near the injury site is preferred for musculoskeletal conditions; oral administration is used for gut conditions. Cycle length is 4–12 weeks depending on the condition being addressed.
BPC-157 modulates the HPA axis, reducing cortisol activity. In women, chronically elevated cortisol disrupts the HPO axis — suppressing LH, FSH, and estrogen production, contributing to irregular cycles, low libido, and thyroid dysfunction. By reducing HPA overactivation, BPC-157 may support a more favorable hormonal environment. It does not directly stimulate or suppress estrogen, progesterone, or other sex hormones.
Yes — gut healing is one of the most well-supported applications of BPC-157 in research. It promotes healing of the intestinal epithelium, reduces intestinal permeability (leaky gut), and modulates gut motility. Women with IBS, IBD, or food sensitivity-related gut dysfunction may benefit from oral BPC-157 protocols (250 mcg twice daily). The gut-brain axis modulation may also support mood and stress resilience.
BPC-157 has a favorable safety profile in research with no documented estrogenic, anti-estrogenic, or androgenic effects. It does not affect the HPTA axis or suppress natural hormone production. The most common side effects are mild injection site reactions. There is no human safety data for use during pregnancy or breastfeeding — BPC-157 should be avoided in these contexts.
Yes — BPC-157 and collagen peptides (particularly Type I and Type III) work synergistically. BPC-157 upregulates the growth factors (VEGF, EGF, TGF-β) that drive collagen synthesis and remodeling, while dietary collagen peptides provide the amino acid substrate (glycine, proline, hydroxyproline) for new collagen formation. This combination is particularly relevant for skin quality, joint health, and connective tissue repair.
BPC-157 is unique in its multi-system healing profile — it addresses gut, musculoskeletal, vascular, and neuroendocrine systems simultaneously. GHK-Cu is more targeted for skin and hair applications. TB-500 provides complementary systemic anti-inflammatory and recovery effects. For women seeking a broad-spectrum healing and recovery peptide, BPC-157 is typically the first-line choice.
There is no direct clinical evidence for BPC-157 in endometriosis or PCOS. However, its anti-inflammatory and HPA axis-modulating properties may indirectly support hormonal balance in these conditions. Women with PCOS who have elevated cortisol and systemic inflammation may benefit from BPC-157's cortisol-reducing effects. This remains speculative — consult a healthcare provider before using BPC-157 for these conditions.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.